2. Cell Cycle/DNA Damage Metabolic Enzyme/Protease Autophagy Anti-infection Apoptosis
  3. HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic
  4. Tanespimycin

Tanespimycin  (Synonyms: 17-AAG; NSC 330507; CP 127374)

Cat. No.: HY-10211 Purity: 99.01%
COA
SDS
Handling Instructions Technical Support

Tanespimycin (17-AAG) est un inhibiteur puissant de HSP90 avec un IC50 de 5 nM, ayant une affinité de liaison 100 fois plus élevée pour la tumeur HSP90 dérivé de cellule que HSP90 dérivé de cellule normale. Tanespimycin épuise les cellules STK38/NDR1 cellulaires et réduit l'activité des kinases STK38. Tanespimycin régule également à la baisse l'expression stk38 du gène.

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.

For research use only. We do not sell to patients.

CAS No. : 75747-14-7

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 69 publication(s) in Google Scholar

Other Forms of Tanespimycin:

Tanespimycin Related Antibodies

Top Publications Citing Use of Products

69 Publications Citing Use of MCE Tanespimycin

IHC
WB

    Tanespimycin purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Apr;51(4):32.  [Abstract]

    Tanespimycin (17‑AAG) inhibits the levels of HSP90 and NLRP3, and decreases GSDMD expression, in MH‑S cells.

    Tanespimycin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Mar 27;37(1):70.  [Abstract]

    Cells are first treated with commercially available HIF-1α inhibitors, including compounds targeting Top1 (Camptothecin, CPT), Top2 (VP; MX) and HSP90 (17-AAG) as well as 2-ME, and then subjected to Western blotting analysis.

    Tanespimycin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 7;9(2):165.  [Abstract]

    Western blot analysis of Hsp70 protein and Hsp90 client proteins IKK and EGFR after 24 h Tan IIA treatment. The Hsp90 inhibitor 17-AAG (10 μM) is included as a positive control

    Tanespimycin purchased from MedChemExpress. Usage Cited in: Front Mol Neurosci. 2018 Nov 6;11:401.  [Abstract]

    Effects of 17-AAG on neurogenesis 4 weeks after SAH.

    Tanespimycin purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2016 Sep;15(9):2107-18.  [Abstract]

    Combination of MDV3100 and 17-AAG leads to decreased AR protein level and transcriptional activity. (A&B) LNCaP (A) and C4-2 (B) cells are treated as indicated for 24 hr, followed by IB against AR, PSA and CHIP. (C&D) 22RV1 (C) and MR49F (D) cells are treated as indicated for 24 hr, followed by IB against AR and HSP90. (E) C4-2 cells are treated as indicated for 24 hr, fractionated into cytoplasm and nuclear, followed by IB against AR and Plk1.

    View All HSP Isoform Specific Products:

    View All Isoforms
    HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].

    IC50 & Target[5]

    HSP90

    5 nM (IC50)

    Autophagy

     

    Mitophagy

     

    Cellular Effect
    Cell Line Type Value Description References
    A-431 IC50
    0.07 3
    Compound: 17-AAG
    Antiproliferative activity against human A431 cells after 72 hrs
    Antiproliferative activity against human A431 cells after 72 hrs
    		[PMID: 20655237]
    A-375 IC50
    1287 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HT-29 IC50
    0.1 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    A-375 IC50
    1287 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    A-375 IC50
    32 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    A-431 IC50
    0.069 3
    Compound: 17-AAG
    Cytotoxicity against human A431 cells after 72 hrs
    Cytotoxicity against human A431 cells after 72 hrs
    		[PMID: 22538015]
    A-375 IC50
    4 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    		[PMID: 19552433]
    A-375 IC50
    32 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    A549 GI50
    0.0075 3
    Compound: III; 17AAG
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    A-431 IC50
    0.069 3
    Compound: 17-AAG
    Cytotoxicity against human A431 cells after 72 hrs
    Cytotoxicity against human A431 cells after 72 hrs
    		[PMID: 22538015]
    A-375 IC50
    4 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    		[PMID: 19552433]
    A549 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    A-431 IC50
    0.07 3
    Compound: 17-AAG
    Antiproliferative activity against human A431 cells after 72 hrs
    Antiproliferative activity against human A431 cells after 72 hrs
    		[PMID: 20655237]
    A-431 IC50
    89 1
    Compound: 17-Aag
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    A-431 IC50
    0.069 3
    Compound: 17-AAG
    Cytotoxicity against human A431 cells after 72 hrs
    Cytotoxicity against human A431 cells after 72 hrs
    		[PMID: 22538015]
    A549 IC50
    0.286 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    A549 IC50
    >10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    A549 IC50
    > 10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    A-431 IC50
    0.07 3
    Compound: 17-AAG
    Antiproliferative activity against human A431 cells after 72 hrs
    Antiproliferative activity against human A431 cells after 72 hrs
    		[PMID: 20655237]
    A549 IC50
    > 10 3
    Compound: 17-AAG
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    A549 IC50
    >10 3
    Compound: 17-AAG
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    A-431 IC50
    89 1
    Compound: 17-Aag
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MCF7 IC50
    0.3 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    A549 GI50
    0.0075 3
    Compound: III; 17AAG
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    A549 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    AU565 IC50
    0.003 3
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    B16-F10 IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against mouse B16F10
    Antiproliferative activity against mouse B16F10
    		[PMID: 21972823]
    A549 IC50
    0.286 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    A549 IC50
    81 1
    Compound: 17-Aag
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    BT-474 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human BT474 cells by MTS assay
    Antiproliferative activity against human BT474 cells by MTS assay
    		[PMID: 17488003]
    AU565 IC50
    0.003 3
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    NCI-N87 GI50
    1 1
    Compound: 3, 17-AAG
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    AU565 IC50
    8 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    CCRF-CEM IC50
    0.1 3
    Compound: 17-AAG
    Antiproliferative activity against human CEM
    Antiproliferative activity against human CEM
    		[PMID: 21972823]
    BGC-823 IC50
    847 1
    Compound: 17-Aag
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    CNE-2 IC50
    3.03 3
    Compound: 17-AAG
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    CNE2Z IC50
    8.41 3
    Compound: 17-AAG
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    BT-474 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human BT474 cells by MTS assay
    Antiproliferative activity against human BT474 cells by MTS assay
    		[PMID: 17488003]
    A-375 IC50
    4 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as Hsp70 induction after 24 hrs by high content screening
    		[PMID: 19552433]
    BT-474 GI50
    5 1
    Compound: 3, 17-AAG
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    DU-145 IC50
    0.282 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    CNE-2 IC50
    3.03 3
    Compound: 17-AAG
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    BT-474 GI50
    5 1
    Compound: 3, 17-AAG
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    CNE2Z IC50
    8.41 3
    Compound: 17-AAG
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    DU-145 IC50
    68.3 3
    Compound: 17-AAG
    Cytotoxicity against DU145 cells after 72 hrs
    Cytotoxicity against DU145 cells after 72 hrs
    		[PMID: 17181154]
    DU-145 IC50
    0.282 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    ECa-109 cell line IC50
    1.1 3
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
    Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
    		[PMID: 23621840]
    DU-145 IC50
    68.3 3
    Compound: 17-AAG
    Cytotoxicity against DU145 cells after 72 hrs
    Cytotoxicity against DU145 cells after 72 hrs
    		[PMID: 17181154]
    MCF7 IC50
    5 1
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    		[PMID: 27153346]
    ECa-109 cell line IC50
    1.1 3
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
    Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
    		[PMID: 23621840]
    GES1 CC50
    7.94 3
    Compound: 4; 17-AAG
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    GES1 CC50
    7.94 3
    Compound: 4; 17-AAG
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HCC827 GI50
    56 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HCT-116 GI50
    0.34 3
    Compound: III; 17AAG
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    HCT-116 GI50
    0.16 3
    Compound: 1b, 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    		[PMID: 18020435]
    HCT-116 GI50
    0.34 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    A549 GI50
    0.0075 3
    Compound: III; 17AAG
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    HCT-116 GI50
    0.16 3
    Compound: 1b, 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    		[PMID: 18020435]
    HCT-116 GI50
    0.34 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    A549 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    A549 IC50
    0.286 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    HCT-116 GI50
    0.16 3
    Compound: 17-AAG
    Inhibition of cell proliferation in HCT116 human colon cancer cell line
    Inhibition of cell proliferation in HCT116 human colon cancer cell line
    		[PMID: 16202589]
    HCT-116 GI50
    0.34 3
    Compound: III; 17AAG
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    HCT-116 GI50
    0.021 3
    Compound: 1b 17AAG
    Inhibition of HCT116 human colon cancer cell proliferation
    Inhibition of HCT116 human colon cancer cell proliferation
    		[PMID: 15955698]
    A549 IC50
    81 1
    Compound: 17-Aag
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    HCT-116 IC50
    202 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human HCT116 cells after 72 hrs
    Cytotoxicity against human HCT116 cells after 72 hrs
    		[PMID: 19231864]
    HCT-116 IC50
    56.5 1
    Compound: 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    		[PMID: 20014866]
    HCT-116 GI50
    0.16 3
    Compound: 17-AAG
    Inhibitory concentration against cell proliferation of human HCT116 cell
    Inhibitory concentration against cell proliferation of human HCT116 cell
    		[PMID: 15974572]
    A549 IC50
    > 10 3
    Compound: 17-AAG
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    HCT-116 IC50
    0.17 3
    Compound: 17-AAG
    Antiproliferative activity against HCT116 cell line
    Antiproliferative activity against HCT116 cell line
    		[PMID: 16480864]
    A549 IC50
    > 10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HCT-15 IC50
    1487 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HCT-116 IC50
    0.145 3
    Compound: 17-AAG
    Antiproliferative activity against human HCT116
    Antiproliferative activity against human HCT116
    		[PMID: 21972823]
    AU565 IC50
    0.003 3
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as Her2 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    HeLa IC50
    > 1000 3
    Compound: III; 17AAG
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    		[PMID: 31655430]
    HCT-15 IC50
    0.41 3
    Compound: 17-AAG
    Antiproliferative activity against human HCT15
    Antiproliferative activity against human HCT15
    		[PMID: 21972823]
    AU565 IC50
    8 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    HeLa IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    HeLa IC50
    108.2 3
    Compound: 17-AAG
    Cytotoxicity against HeLa cells after 72 hrs
    Cytotoxicity against HeLa cells after 72 hrs
    		[PMID: 17181154]
    AU565 IC50
    8 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human AU565 cells assessed as pERK degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    B16-F10 IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against mouse B16F10
    Antiproliferative activity against mouse B16F10
    		[PMID: 21972823]
    HeLa IC50
    128 1
    Compound: 17-Aag
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    BGC-823 IC50
    847 1
    Compound: 17-Aag
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    PC-3 IC50
    9 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MV4-11 GI50
    11 1
    Compound: 3, 17-AAG
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HeLa IC50
    19.4 3
    Compound: 17-AAG
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    BT-474 GI50
    5 1
    Compound: 3, 17-AAG
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    Growth inhibition of human BT474 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    BT-474 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human BT474 cells by MTS assay
    Antiproliferative activity against human BT474 cells by MTS assay
    		[PMID: 17488003]
    MCF7 EC50
    12 1
    Compound: 1, 17-AAG, tanespimycin
    Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2
    Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2
    		[PMID: 22938030]
    Hep 3B2 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    MCF7 IC50
    12 1
    Compound: 3, 17-AAG, KOS953, CNF-1010
    Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells
    Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells
    		[PMID: 20055425]
    CCRF-CEM IC50
    0.1 3
    Compound: 17-AAG
    Antiproliferative activity against human CEM
    Antiproliferative activity against human CEM
    		[PMID: 21972823]
    HepG2 IC50
    0.32 3
    Compound: 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    MCF7 IC50
    15 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation
    Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation
    		[PMID: 19017562]
    CNE-2 IC50
    3.03 3
    Compound: 17-AAG
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human CNE-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    HepG2 IC50
    0.33 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-OV-3 GI50
    15 1
    Compound: 1b, 17-AAG
    Inhibition of human SKOV3 cell growth
    Inhibition of human SKOV3 cell growth
    		[PMID: 16854066]
    HepG2 IC50
    8 3
    Compound: 17-AAG
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    CNE2Z IC50
    8.41 3
    Compound: 17-AAG
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    HepG2 IC50
    91 1
    Compound: 17-Aag
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    HeLa IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    HT-29 IC50
    0.1 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HeLa IC50
    108.2 3
    Compound: 17-AAG
    Cytotoxicity against HeLa cells after 72 hrs
    Cytotoxicity against HeLa cells after 72 hrs
    		[PMID: 17181154]
    HeLa IC50
    19.4 3
    Compound: 17-AAG
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    DU-145 IC50
    0.282 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    HUVEC GI50
    < 0.1 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    HUVEC IC50
    282 1
    Compound: 17-Aag
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    HeLa IC50
    >1 2
    Compound: III; 17AAG
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    		[PMID: 31655430]
    DU-145 IC50
    68.3 3
    Compound: 17-AAG
    Cytotoxicity against DU145 cells after 72 hrs
    Cytotoxicity against DU145 cells after 72 hrs
    		[PMID: 17181154]
    K562 IC50
    0.15 3
    Compound: 1, 17-AAG
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    		[PMID: 24565573]
    SK-BR-3 GI50
    17 1
    Compound: 1b, 17-AAG
    Inhibition of human SKBR3 cell growth
    Inhibition of human SKBR3 cell growth
    		[PMID: 16854066]
    GES1 CC50
    7.94 3
    Compound: 4; 17-AAG
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    Hep 3B2 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    K562 IC50
    126 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    K562 GI50
    48 1
    Compound: 3, 17-AAG
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HepG2 IC50
    0.32 3
    Compound: 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    HepG2 IC50
    0.33 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    L02 CC50
    11.65 3
    Compound: 4; 17-AAG
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    L02 IC50
    99 1
    Compound: 17-Aag
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-OV-3 EC50
    19 1
    Compound: 1b, 17-AAG
    Degradation of Her2 in SKOV3 cells
    Degradation of Her2 in SKOV3 cells
    		[PMID: 16854066]
    HepG2 IC50
    8 3
    Compound: 17-AAG
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    HCC827 GI50
    56 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    LNCaP IC50
    0.16 3
    Compound: 17-AAG
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    LNCaP IC50
    82 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HL-60 IC50
    0.06 3
    Compound: 17-AAG
    Antiproliferative activity against human HL60
    Antiproliferative activity against human HL60
    		[PMID: 21972823]
    SK-BR-3 EC50
    22 1
    Compound: 1b, 17-AAG
    Upregulation of Hsp70 in SKBR3 cells
    Upregulation of Hsp70 in SKBR3 cells
    		[PMID: 16854066]
    LoVo IC50
    0.26 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MCF7 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells by MTS assay
    Antiproliferative activity against human MCF7 cells by MTS assay
    		[PMID: 17488003]
    HT-29 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human HT-29
    Antiproliferative activity against human HT-29
    		[PMID: 21972823]
    HT-29 IC50
    0.002 3
    Compound: 17-AAG
    Antiproliferative activity against human HT29 cells
    Antiproliferative activity against human HT29 cells
    		[PMID: 17488003]
    MCF7 IC50
    0.029 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    SK-BR-3 IC50
    27 1
    Compound: 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    		[PMID: 15844961]
    MCF7 IC50
    0.09 3
    Compound: 1b, 17-AAG
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 21920765]
    HUVEC GI50
    <0.1 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    HCT-116 GI50
    0.021 3
    Compound: 1b 17AAG
    Inhibition of HCT116 human colon cancer cell proliferation
    Inhibition of HCT116 human colon cancer cell proliferation
    		[PMID: 15955698]
    MCF7 IC50
    0.192 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    MCF7 IC50
    0.3 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HCT-116 GI50
    0.16 3
    Compound: 17-AAG
    Inhibitory concentration against cell proliferation of human HCT116 cell
    Inhibitory concentration against cell proliferation of human HCT116 cell
    		[PMID: 15974572]
    SK-BR-3 IC50
    31 1
    Compound: 1c
    In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells
    In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells
    		[PMID: 7562912]
    SK-BR-3 IC50
    31 1
    Compound: 2, 17-AAG
    Inhibition of Her2 in human SKBR3 cells
    Inhibition of Her2 in human SKBR3 cells
    		[PMID: 19017562]
    HCT-116 GI50
    0.16 3
    Compound: 17-AAG
    Inhibition of cell proliferation in HCT116 human colon cancer cell line
    Inhibition of cell proliferation in HCT116 human colon cancer cell line
    		[PMID: 16202589]
    MCF7 IC50
    5 1
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    		[PMID: 27153346]
    SK-BR-3 IC50
    31 1
    Compound: 1b5
    Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.
    Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.
    		[PMID: 7562911]
    HCT-116 GI50
    0.16 3
    Compound: 1b, 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    Growth inhibition of human HCT116 cells after 24 hrs by SRB assay
    		[PMID: 18020435]
    MCF7 IC50
    58 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs
    Cytotoxicity against human MCF7 cells after 72 hrs
    		[PMID: 19231864]
    A-375 IC50
    32 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    Inhibition of Hsp90 in human A375 cells assessed as pS6 degradation after 24 hrs by high content screening
    		[PMID: 19552433]
    HCT-116 GI50
    0.34 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    MCF7 IC50
    662 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    SK-BR-3 IC50
    33 1
    Compound: 2, 17-AAG
    Binding affinity to Hsp90 in human SKBR3 cells
    Binding affinity to Hsp90 in human SKBR3 cells
    		[PMID: 19017562]
    HCT-116 GI50
    0.34 3
    Compound: III; 17AAG
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    MDA-MB-231 GI50
    0.27 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-Aag
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-BR-3 IC50
    33 1
    Compound: 1b, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    		[PMID: 19405528]
    HCT-116 IC50
    0.145 3
    Compound: 17-AAG
    Antiproliferative activity against human HCT116
    Antiproliferative activity against human HCT116
    		[PMID: 21972823]
    HCT-116 IC50
    0.17 3
    Compound: 17-AAG
    Antiproliferative activity against HCT116 cell line
    Antiproliferative activity against HCT116 cell line
    		[PMID: 16480864]
    K562 IC50
    0.15 3
    Compound: 1, 17-AAG
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    		[PMID: 24565573]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-AAG
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    NCI-H1975 GI50
    35 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HCT-116 IC50
    202 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human HCT116 cells after 72 hrs
    Cytotoxicity against human HCT116 cells after 72 hrs
    		[PMID: 19231864]
    MDA-MB-231 IC50
    0.52 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    SK-BR-3 EC50
    35 1
    Compound: 1b, 17-AAG
    Degradation of Her2 in SKBR3 cells
    Degradation of Her2 in SKBR3 cells
    		[PMID: 16854066]
    HCT-116 IC50
    56.5 1
    Compound: 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    		[PMID: 20014866]
    MDA-MB-231 IC50
    1.79 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    L02 CC50
    11.65 3
    Compound: 4; 17-AAG
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MDA-MB-231 IC50
    194 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    SK-BR-3 IC50
    44 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs
    Cytotoxicity against human SKBR3 cells after 72 hrs
    		[PMID: 19231864]
    HCT-15 IC50
    0.41 3
    Compound: 17-AAG
    Antiproliferative activity against human HCT15
    Antiproliferative activity against human HCT15
    		[PMID: 21972823]
    MDA-MB-468 IC50
    1.57 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    K562 GI50
    48 1
    Compound: 3, 17-AAG
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HCT-15 IC50
    1487 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MDA-MB-468 IC50
    1500 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    		[PMID: 19231864]
    MDA-MB-468 GI50
    780 1
    Compound: 3, 17-AAG
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    LNCaP IC50
    0.16 3
    Compound: 17-AAG
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    MRC5 CC50
    14.24 3
    Compound: 4; 17-AAG
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HL-60 IC50
    0.06 3
    Compound: 17-AAG
    Antiproliferative activity against human HL60
    Antiproliferative activity against human HL60
    		[PMID: 21972823]
    LoVo IC50
    0.26 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HCC827 GI50
    56 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant HCC827 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HT-29 IC50
    0.002 3
    Compound: 17-AAG
    Antiproliferative activity against human HT29 cells
    Antiproliferative activity against human HT29 cells
    		[PMID: 17488003]
    MV4-11 GI50
    11 1
    Compound: 3, 17-AAG
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    HCT-116 IC50
    56.5 1
    Compound: 17-AAG
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    Growth inhibition of human HCT116 cells after 24 hrs by [3H]thymidine uptake assay
    		[PMID: 20014866]
    HT-29 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human HT-29
    Antiproliferative activity against human HT-29
    		[PMID: 21972823]
    NCI-H1299 IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 28426997]
    MCF7 IC50
    58 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs
    Cytotoxicity against human MCF7 cells after 72 hrs
    		[PMID: 19231864]
    HT-29 IC50
    0.1 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HT-29 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    NCI-H1975 GI50
    0.16 3
    Compound: III; 17AAG
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    HUVEC GI50
    < 0.1 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human HUVEC cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    MCF7 IC50
    0.192 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    NCI-H1975 GI50
    35 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    MCF7 IC50
    0.09 3
    Compound: 1b, 17-AAG
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 21920765]
    NCI-H460 IC50
    0.01 3
    Compound: 17-AAG
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    		[PMID: 22538015]
    HUVEC IC50
    282 1
    Compound: 17-Aag
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    NCI-H460 IC50
    255 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MCF7 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells by MTS assay
    Antiproliferative activity against human MCF7 cells by MTS assay
    		[PMID: 17488003]
    MCF7 IC50
    0.029 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    NCI-H596 IC50
    1600 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    		[PMID: 19231864]
    HeLa IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    MCF7 IC50
    0.005 3
    Compound: 49; 17-AAG
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    HeLa IC50
    108.2 3
    Compound: 17-AAG
    Cytotoxicity against HeLa cells after 72 hrs
    Cytotoxicity against HeLa cells after 72 hrs
    		[PMID: 17181154]
    NCI-N87 GI50
    1 1
    Compound: 3, 17-AAG
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    MCF7 IC50
    0.02 3
    Compound: 17-AAG
    Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding
    Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding
    		[PMID: 17488003]
    NCM460 CC50
    14.21 3
    Compound: 4; 17-AAG
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HeLa IC50
    128 1
    Compound: 17-Aag
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MCF7 IC50
    0.007 3
    Compound: 17-AAG
    Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation
    Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation
    		[PMID: 17488003]
    OVCAR-3 IC50
    0.48 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HeLa IC50
    19.4 3
    Compound: 17-AAG
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    MCF7 IC50
    >500 3
    Compound: 17AAG
    Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells
    Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells
    		[PMID: 11294389]
    PANC-1 IC50
    3.21 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HeLa IC50
    > 1000 3
    Compound: III; 17AAG
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys(acetyl)-AMC as substrate measured after 30 mins by fluorescence assay
    		[PMID: 31655430]
    PC-3 IC50
    0.062 3
    Compound: 17-AAG
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    MCF7 IC50
    50 3
    Compound: 17-AAG
    Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells
    Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells
    		[PMID: 17488003]
    PC-3 IC50
    9 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MDA-MB-231 GI50
    0.27 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    Hep 3B2 GI50
    0.08 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human Hep3B cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    HepG2 IC50
    0.32 3
    Compound: 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    SGC-7901 IC50
    > 10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MDA-MB-231 IC50
    0.52 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    SK-BR-3 EC50
    < 0.1 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    		[PMID: 21106457]
    MDA-MB-231 IC50
    1.79 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    HepG2 IC50
    0.33 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-BR-3 IC50
    0.038 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-AAG
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    HepG2 IC50
    8 3
    Compound: 17-AAG
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33543615]
    SK-BR-3 EC50
    0.06 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    		[PMID: 21106457]
    HepG2 IC50
    91 1
    Compound: 17-Aag
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-Aag
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-BR-3 IC50
    27 1
    Compound: 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    		[PMID: 15844961]
    A549 IC50
    81 1
    Compound: 17-Aag
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-BR-3 IC50
    33 1
    Compound: 1b, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    		[PMID: 19405528]
    LNCaP IC50
    82 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    K562 GI50
    48 1
    Compound: 3, 17-AAG
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    Growth inhibition of human K562 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    MDA-MB-468 IC50
    1.57 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    K562 IC50
    0.15 3
    Compound: 1, 17-AAG
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay
    		[PMID: 24565573]
    SK-BR-3 IC50
    410 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    K562 IC50
    126 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    A-431 IC50
    89 1
    Compound: 17-Aag
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-BR-3 IC50
    44 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs
    Cytotoxicity against human SKBR3 cells after 72 hrs
    		[PMID: 19231864]
    HepG2 IC50
    91 1
    Compound: 17-Aag
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-MEL-5 IC50
    134 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    L02 CC50
    11.65 3
    Compound: 4; 17-AAG
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-OV-3 IC50
    0.22 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    L02 IC50
    99 1
    Compound: 17-Aag
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    L02 IC50
    99 1
    Compound: 17-Aag
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MRC5 CC50
    14.24 3
    Compound: 4; 17-AAG
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    LNCaP IC50
    0.16 3
    Compound: 17-AAG
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    SK-OV-3 IC50
    240 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKOV3 cells after 72 hrs
    Cytotoxicity against human SKOV3 cells after 72 hrs
    		[PMID: 19231864]
    SMMC-7721 IC50
    0.19 3
    Compound: 17-AAG
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    LNCaP IC50
    82 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human LNCAP cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    K562 IC50
    126 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human K562 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    LoVo IC50
    0.26 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    HeLa IC50
    128 1
    Compound: 17-Aag
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SW480 IC50
    0.28 3
    Compound: 17-AAG
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    SW480 IC50
    572 1
    Compound: 17-Aag
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    SK-MEL-5 IC50
    134 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MCF7 EC50
    12 1
    Compound: 1, 17-AAG, tanespimycin
    Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2
    Inhibition of HSP90alpha in human MCF7 cells assessed as degradation of Her-2
    		[PMID: 22938030]
    SW-620 IC50
    328 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MDA-MB-231 IC50
    194 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MCF7 IC50
    0.005 3
    Compound: 49; 17-AAG
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition
    Antitumor activity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    U-87MG ATCC IC50
    > 10 3
    Compound: 17-AAG
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    MCF7 IC50
    0.007 3
    Compound: 17-AAG
    Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation
    Inhibition of human recombinant HSP90 in MCF7 cells assessed as Her2 degradation
    		[PMID: 17488003]
    MX1 IC50
    0.045 3
    Compound: 17-AAG
    Antiproliferative activity against human MX1
    Antiproliferative activity against human MX1
    		[PMID: 21972823]
    HCT-116 IC50
    202 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human HCT116 cells after 72 hrs
    Cytotoxicity against human HCT116 cells after 72 hrs
    		[PMID: 19231864]
    MCF7 IC50
    0.01 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells by MTS assay
    Antiproliferative activity against human MCF7 cells by MTS assay
    		[PMID: 17488003]
    NCI-H1299 IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 28426997]
    MCF7 IC50
    0.02 3
    Compound: 17-AAG
    Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding
    Binding affinity to human recombinant HSP90 in MCF7 cell lysates assessed as inhibition of biotinylated-geldanamycin binding
    		[PMID: 17488003]
    NCI-H1975 GI50
    0.16 3
    Compound: III; 17AAG
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    MCF7 IC50
    0.029 3
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    SK-OV-3 IC50
    240 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKOV3 cells after 72 hrs
    Cytotoxicity against human SKOV3 cells after 72 hrs
    		[PMID: 19231864]
    MCF7 IC50
    0.09 3
    Compound: 1b, 17-AAG
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 21920765]
    NCI-H460 IC50
    0.03 3
    Compound: 17-AAG
    Antiproliferative activity against human NCI-H460
    Antiproliferative activity against human NCI-H460
    		[PMID: 21972823]
    MCF7 IC50
    0.192 3
    Compound: 2; 17-AAG
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28073608]
    NCI-H460 IC50
    255 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MCF7 IC50
    0.3 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MCF7 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    NCI-H460 IC50
    0.01 3
    Compound: 17-AAG
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    		[PMID: 22538015]
    MCF7 IC50
    12 1
    Compound: 3, 17-AAG, KOS953, CNF-1010
    Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells
    Inhibition of HSP90-mediated client protein HER2 degradation in human MCF7 cells
    		[PMID: 20055425]
    HUVEC IC50
    282 1
    Compound: 17-Aag
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MCF7 IC50
    15 1
    Compound: 2, 17-AAG
    Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation
    Inhibition of Hsp90 in human MCF7 cells assessed as Her2 degradation
    		[PMID: 19017562]
    NCM460 CC50
    14.21 3
    Compound: 4; 17-AAG
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MCF7 IC50
    5 1
    Compound: 17-AAG
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    Antiproliferative activity against human MCF7 cells measured after 5 days by MTS assay
    		[PMID: 27153346]
    MCF7 IC50
    50 3
    Compound: 17-AAG
    Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells
    Selectivity for HSP90 in MCF7 cells over HSP90 in NDF cells
    		[PMID: 17488003]
    SW-620 IC50
    328 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    OVCAR-3 IC50
    0.48 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MCF7 IC50
    58 1
    Compound: 2a; 17-AAG
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 39361055]
    MCF7 IC50
    58 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs
    Cytotoxicity against human MCF7 cells after 72 hrs
    		[PMID: 19231864]
    PANC-1 IC50
    3.21 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-BR-3 IC50
    410 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    MCF7 IC50
    662 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    PC-3 IC50
    0.13 3
    Compound: 17-AAG
    Antiproliferative activity against human PC3
    Antiproliferative activity against human PC3
    		[PMID: 21972823]
    MCF7 IC50
    > 500 3
    Compound: 17AAG
    Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells
    Inhibition of Phoshoinositol 3 kinase from MCF-7 breast cancer cells
    		[PMID: 11294389]
    PC-3 IC50
    0.062 3
    Compound: 17-AAG
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    SW480 IC50
    572 1
    Compound: 17-Aag
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MCF7 IC50
    662 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human MCF7 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    MDA-MB-231 GI50
    0.27 3
    Compound: 1; 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by Sulforhodamine B assay
    		[PMID: 33934008]
    MDA-MB-468 GI50
    780 1
    Compound: 3, 17-AAG
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-AAG
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25105924]
    MDA-MB-231 IC50
    0.28 3
    Compound: 17-Aag
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    RPTEC IC50
    0.1 3
    Compound: 17-AAG
    Antiproliferative activity against human RPTEC
    Antiproliferative activity against human RPTEC
    		[PMID: 17488003]
    RPTEC IC50
    50 3
    Compound: 17-AAG
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells
    		[PMID: 17488003]
    MDA-MB-231 IC50
    0.52 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 27266997]
    MDA-MB-231 IC50
    1.79 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    RPTEC IC50
    10 3
    Compound: 17-AAG
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells
    		[PMID: 17488003]
    BGC-823 IC50
    847 1
    Compound: 17-Aag
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    MDA-MB-231 IC50
    194 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human MDA-MB-231 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    A-375 IC50
    1287 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human A375 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    HCT-15 IC50
    1487 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human HCT15 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    MDA-MB-468 IC50
    1500 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    		[PMID: 19231864]
    MDA-MB-468 GI50
    780 1
    Compound: 3, 17-AAG
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    Growth inhibition of human MDA-MB-468 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    NCI-H596 IC50
    1600 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    		[PMID: 19231864]
    SGC-7901 IC50
    >10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    MDA-MB-468 IC50
    1.57 3
    Compound: 17-AAG
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 27153346]
    SK-BR-3 EC50
    0.025 3
    Compound: 1, 17-AAG
    Cytotoxicity against human SKBR3 cells
    Cytotoxicity against human SKBR3 cells
    		[PMID: 21106457]
    MDA-MB-468 IC50
    1500 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human MDA468 cells after 72 hrs
    		[PMID: 19231864]
    SK-BR-3 EC50
    <0.1 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    		[PMID: 21106457]
    MRC5 CC50
    14.24 3
    Compound: 4; 17-AAG
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-BR-3 EC50
    0.06 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    		[PMID: 21106457]
    MV4-11 GI50
    11 1
    Compound: 3, 17-AAG
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    Growth inhibition of human MV4-11 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    SK-BR-3 IC50
    0.025 3
    Compound: 17-AAG
    Antiproliferative activity against human SKBR3
    Antiproliferative activity against human SKBR3
    		[PMID: 21972823]
    MX1 IC50
    0.045 3
    Compound: 17-AAG
    Antiproliferative activity against human MX1
    Antiproliferative activity against human MX1
    		[PMID: 21972823]
    SK-BR-3 IC50
    0.038 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    NCI-H1299 IC50
    0.2 3
    Compound: 17-AAG
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    Antiproliferative activity against human H1299 cells after 48 hrs by resazurin dye-based fluorescence assay
    		[PMID: 28426997]
    SK-BR-3 IC50
    0.004 3
    Compound: 49; 17-AAG
    Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition
    Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    SK-OV-3 IC50
    0.22 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    NCI-H1975 GI50
    0.16 3
    Compound: III; 17AAG
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
    		[PMID: 31655430]
    SMMC-7721 IC50
    0.19 3
    Compound: 17-AAG
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    NCI-H1975 GI50
    35 1
    Compound: 3, 17-AAG
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    Growth inhibition of human tarceva and iressa-resistant NCI-H1975 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    SW480 IC50
    0.28 3
    Compound: 17-AAG
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    NCI-H460 IC50
    0.01 3
    Compound: 17-AAG
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    Cytotoxicity against human NCI-H460 cells after 72 hrs
    		[PMID: 22538015]
    U-87MG ATCC IC50
    >10 3
    Compound: 17-AAG
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    NCI-H460 IC50
    0.03 3
    Compound: 17-AAG
    Antiproliferative activity against human NCI-H460
    Antiproliferative activity against human NCI-H460
    		[PMID: 21972823]
    NCI-H460 IC50
    255 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human NCI-H460 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    NCI-H596 IC50
    1600 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    Cytotoxicity against NQ01-deficient human NCI-H596 cells after 72 hrs
    		[PMID: 19231864]
    NCI-N87 GI50
    1 1
    Compound: 3, 17-AAG
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    Growth inhibition of human NCI-N87 cells assessed as ATP level after 4 days
    		[PMID: 19410458]
    NCM460 CC50
    14.21 3
    Compound: 4; 17-AAG
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    OVCAR-3 IC50
    0.48 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    PANC-1 IC50
    3.21 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    PC-3 IC50
    0.062 3
    Compound: 17-AAG
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    PC-3 IC50
    0.13 3
    Compound: 17-AAG
    Antiproliferative activity against human PC3
    Antiproliferative activity against human PC3
    		[PMID: 21972823]
    PC-3 IC50
    9 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human PC3 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    RPTEC IC50
    0.1 3
    Compound: 17-AAG
    Antiproliferative activity against human RPTEC
    Antiproliferative activity against human RPTEC
    		[PMID: 17488003]
    RPTEC IC50
    10 3
    Compound: 17-AAG
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for MCF7 cells
    		[PMID: 17488003]
    RPTEC IC50
    50 3
    Compound: 17-AAG
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells
    Selectivity index, ratio of IC50 for human RPTEC cells to IC50 for HT29 cells
    		[PMID: 17488003]
    SGC-7901 IC50
    > 10 3
    Compound: 4; 17-AAG
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay
    		[PMID: 33189438]
    SK-BR-3 EC50
    0.025 3
    Compound: 1, 17-AAG
    Cytotoxicity against human SKBR3 cells
    Cytotoxicity against human SKBR3 cells
    		[PMID: 21106457]
    SK-BR-3 EC50
    0.06 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as up-regulation of HSP70 protein by Western blot analysis
    		[PMID: 21106457]
    SK-BR-3 EC50
    22 1
    Compound: 1b, 17-AAG
    Upregulation of Hsp70 in SKBR3 cells
    Upregulation of Hsp70 in SKBR3 cells
    		[PMID: 16854066]
    SK-BR-3 EC50
    35 1
    Compound: 1b, 17-AAG
    Degradation of Her2 in SKBR3 cells
    Degradation of Her2 in SKBR3 cells
    		[PMID: 16854066]
    SK-BR-3 EC50
    < 0.1 3
    Compound: 1, 17-AAG
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    Inhibition of Hsp90alpha in human SKBR3 cells assessed as ErbB2 degradation by Western blot analysis
    		[PMID: 21106457]
    SK-BR-3 GI50
    17 1
    Compound: 1b, 17-AAG
    Inhibition of human SKBR3 cell growth
    Inhibition of human SKBR3 cell growth
    		[PMID: 16854066]
    SK-BR-3 IC50
    0.004 3
    Compound: 49; 17-AAG
    Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition
    Antitumor activity against human SK-BR-3 cells assessed as cell growth inhibition
    		[PMID: 36858050]
    SK-BR-3 IC50
    0.025 3
    Compound: 17-AAG
    Antiproliferative activity against human SKBR3
    Antiproliferative activity against human SKBR3
    		[PMID: 21972823]
    SK-BR-3 IC50
    0.038 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    SK-BR-3 IC50
    27 1
    Compound: 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-Glo assay
    		[PMID: 15844961]
    SK-BR-3 IC50
    31 1
    Compound: 1b5
    Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.
    Inhibition of oncogene product p185 erbB-2 from human breast cancer cells(SK-BR-3 cells) at 50 mg/kg dose.
    		[PMID: 7562911]
    SK-BR-3 IC50
    31 1
    Compound: 1c
    In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells
    In vitro inhibition of p185 erbB-2 oncoprotein in human breast cancer SK-BR-3 cells
    		[PMID: 7562912]
    SK-BR-3 IC50
    31 1
    Compound: 2, 17-AAG
    Inhibition of Her2 in human SKBR3 cells
    Inhibition of Her2 in human SKBR3 cells
    		[PMID: 19017562]
    SK-BR-3 IC50
    33 1
    Compound: 1b, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    		[PMID: 19405528]
    SK-BR-3 IC50
    33 1
    Compound: 2, 17-AAG
    Binding affinity to Hsp90 in human SKBR3 cells
    Binding affinity to Hsp90 in human SKBR3 cells
    		[PMID: 19017562]
    SK-BR-3 IC50
    410 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    Cytotoxicity against human SKBR3 cells after 72 hrs in presence of NQO1 inhibitor dicoumarol
    		[PMID: 19231864]
    SK-BR-3 IC50
    44 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKBR3 cells after 72 hrs
    Cytotoxicity against human SKBR3 cells after 72 hrs
    		[PMID: 19231864]
    SK-MEL-5 IC50
    134 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SK-MEL-5 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    SK-OV-3 EC50
    19 1
    Compound: 1b, 17-AAG
    Degradation of Her2 in SKOV3 cells
    Degradation of Her2 in SKOV3 cells
    		[PMID: 16854066]
    SK-OV-3 GI50
    15 1
    Compound: 1b, 17-AAG
    Inhibition of human SKOV3 cell growth
    Inhibition of human SKOV3 cell growth
    		[PMID: 16854066]
    SK-OV-3 IC50
    0.22 3
    Compound: 17-AAG
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    SK-OV-3 IC50
    240 1
    Compound: 2a; 17-AAG
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 39361055]
    SK-OV-3 IC50
    240 1
    Compound: Tanespimycin, 17-AAG
    Cytotoxicity against human SKOV3 cells after 72 hrs
    Cytotoxicity against human SKOV3 cells after 72 hrs
    		[PMID: 19231864]
    SMMC-7721 IC50
    0.19 3
    Compound: 17-AAG
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    SW-620 IC50
    328 1
    Compound: 2, 17-AAG
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    Antiproliferative activity against human SW620 cells after 72 to 144 hrs by cyquant DNA dye method
    		[PMID: 19552433]
    SW480 IC50
    0.28 3
    Compound: 17-AAG
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    		[PMID: 32527461]
    SW480 IC50
    572 1
    Compound: 17-Aag
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 25277067]
    U-87MG ATCC IC50
    > 10 3
    Compound: 17-AAG
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    		[PMID: 32663707]
    In Vitro

    Tanespimycin causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. Tanespimycin inhibits prostate cancer cell lines with IC50s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM)[1].
    Tanespimycin (0.1-1 μM) induces a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells[2]. Tanespimycin inhibits cell growth and induces G2/M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B1, and the up-regulation of cleaved PARP[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Tanespimycin Related Antibodies
    In Vivo

    Tanespimycin (25-200 mg/kg, i.p.) causes a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. Tanespimycin treatment at doses sufficient to induce AR, HER2, and Akt degradation results in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity[1].
    Tanespimycin (60 mg/kg) with Rapamycin (30 mg/kg) inhibits A549 and MDA-MB-231 tumor growth and effects tumor cures in MDA-MB-231 tumor-bearing animals by tail vein injection[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    585.69

    Formula

    C31H43N3O8
    CAS No.
    Appearance

    Solid

    Color

    Purple to purplish red

    SMILES

    O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (85.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7074 mL 8.5369 mL 17.0739 mL
    5 mM 0.3415 mL 1.7074 mL 3.4148 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (8.54 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 5 mg/mL (8.54 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (17.07 mM); Suspended solution; Need ultrasonic

    • Protocol 2

      Add each solvent one by one:  15% Cremophor EL    85% Saline

      Solubility: 5 mg/mL (8.54 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.01%

    SDS (393 KB)

    COA (251 KB) LCMS (96 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    For the Alamar Blue proliferation assay, 2-4×103 cells are plated in 96-well plates. Later (48 h), cells are treated with Tanespimycin for 96 h or 0.01% DMSO as control. On day 4, Alamar Blue viability assay is performed as described elsewhere. IC50 and IC90s are calculated as the doses of Tanespimycin required to inhibit cell growth by 50 and 90%, respectively. Cell cycle distribution is assayed as described previously with a Becton Dickinson fluorescence-activated cell sorter and analyzed by the Cell Cycle Multicycle system.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Tanespimycin is dissolved in an EPL vehicle. To aid in the identification of an optimal dose and schedule, nontumor bearing mice are treated by i.p. injection with 25-200 mg/kg of Tanespimycin 5 days/week for 3 weeks or by the EPL vehicle alone. Serum samples are taken from each group, and equal volumes are pooled on days 5, 10, and 15 of treatment for serum chemistry and liver function analysis. At sacrifice, plasma samples are collected for complete blood count. A gross necropsy is performed on all of the mice, and a complete necropsy, including histopathology, is performed on 1 animal/group.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7074 mL 8.5369 mL 17.0739 mL 42.6847 mL
    5 mM 0.3415 mL 1.7074 mL 3.4148 mL 8.5369 mL
    10 mM 0.1707 mL 0.8537 mL 1.7074 mL 4.2685 mL
    15 mM 0.1138 mL 0.5691 mL 1.1383 mL 2.8456 mL
    20 mM 0.0854 mL 0.4268 mL 0.8537 mL 2.1342 mL
    25 mM 0.0683 mL 0.3415 mL 0.6830 mL 1.7074 mL
    30 mM 0.0569 mL 0.2846 mL 0.5691 mL 1.4228 mL
    40 mM 0.0427 mL 0.2134 mL 0.4268 mL 1.0671 mL
    50 mM 0.0341 mL 0.1707 mL 0.3415 mL 0.8537 mL
    60 mM 0.0285 mL 0.1423 mL 0.2846 mL 0.7114 mL
    80 mM 0.0213 mL 0.1067 mL 0.2134 mL 0.5336 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tanespimycin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tanespimycin75747-14-717-AAG NSC 330507 CP 127374NSC330507NSC 330507NSC-330507CP127374CP 127374CP-127374HSPAutophagyMitophagyBacterialApoptosisAntibioticHeat shock proteinsMitochondrial AutophagyARHER2A549MDA-MB-231tumorprostatecancerstk38Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tanespimycin
    Cat. No.:
    HY-10211
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.